WHAT IS CLAIMED IS:

1. A compound having the structure **(I)**:



I

wherein:

R_1 to R_3 are each independently –H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl,

each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,

E_1 to E_4 are each independently –O, -NR_5, or –S, wherein R_5 is –H or C_1-C_6 alkyl, and

x is 0 to 8.

2. The compound of claim 1, wherein E_1, E_3, and E_4 are –O, and E_2 is –NH.

3. The compound of claim 1, wherein R_1 and R_2 are –H, alkyl, or substituted alkyl, and R_3 is hydroxy or alkoxy.

4. The compound of claim 1, wherein R_1 is substituted alkyl.

5. The compound of claim 4, wherein the substituted alkyl is a halogenated alkyl.

6. The compound of claim 5, wherein the halogenated alkyl is a chlorinated alkyl.

7. A compound having the structure:



8. A pharmaceutical composition comprising at least one compound of claim 1 in a pharmaceutically acceptable carrier therefor.

9. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treatment of cell proliferative disorders and wherein said pharmaceutical composition comprises at least one compound of claim 1.

10. A pharmaceutical composition useful for inhibiting proliferation of hyperproliferative mammalian cells, comprising an effective amount of a pharmaceutically acceptable carrier and a compound having the structure:



I

wherein:

R_1 to R_3 are each independently –H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl,

each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,

E_1 to E_4 are each independently –O, -NR_5, or –S, wherein R_5 is –H or C_1-C_6 alkyl, and

x is 0 to 8.

11. The pharmaceutical composition of claim 10, further comprising at least one additional anti-neoplastic agent.

12. A pharmaceutical composition useful for inhibiting proliferation of hyperproliferative mammalian cells, comprising an effective amount of a pharmaceutically acceptable carrier and a compound having the structure:



13. A method for treating a mammalian cell proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure:



I

wherein:

R_1 to R_3 are each independently –H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl,

each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,

E_1 to E_4 are each independently –O, -NR_5, or –S, wherein R_5 is –H or C_1-C_6 alkyl, and

x is 0 to 8'

thereby treating a mammalian cell proliferative disorder.

14. The method of claim 13, wherein the compound has the structure:



15. The method of claim 13, wherein the mammalian cell is human.

16. The method of claim 13, wherein the disorder is characterized by the formation of neoplasms.

17. The method of claim 16, wherein the neoplasms are selected from mammory, small-cell lung, non-small-cell lung, colorectal, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system (CNS), ovarian, prostate, sarccff of soft tissue or bone, head and neck, gastric which includes thyroid and non-Hodgkin's disease, stomach, myeloma, bladder, renal, neuroendocrine which includes thyroid and non-Hodgkin's disease and Hodgkin's disease neoplasms.

18. The method of claim 17, wherein the neoplasms are colorectal neoplasms.

19. A method for inhibiting proliferation of mammalian cells, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

20. The method of claim 19, wherein the mammalian cells are human.

21. The method of claim 20, wherein the cells are selected from mammory, small-cell lung, non-small-cell lung, colorectal, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system (CNS), ovarian, prostate, sarccff of soft tissue or bone, head and neck, gastric, stomach, myeloma, bladder, renal, and neuroendocrine cells.

22. A method for producing a compound having the ability to inhibit the proliferation of hyperproliferative mammalian cells, wherein said compound has structure **(I)**:



I

wherein:

R_1 to R_3 are each independently –H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl,

each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,

E_1 to E_4 are each independently –O, $-NR_5$, or –S, wherein R_5 is –H or C_1-C_6 alkyl, and

x is 0 to 8,

the method comprising:

a) cultivating a culture of a *Salinospora* sp. strain CNB392 or CNB476;

b) isolating from the culture at least one compound of structure **(I)**.